The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations

Soysal T., Eskazan A. E. , Serin I., Sadri S., Keskin D., Yurttas N. O. , ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.7, 2019 (Peer-Reviewed Journal) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 7
  • Publication Date: 2019
  • Doi Number: 10.1016/j.clml.2019.03.028
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Keywords: Chronic myeloid leukemia, European LeukemiaNet (ELN), Imatinib, Tyrosine kinase inhibitor, Warning, MANAGEMENT


We retrospectively evaluated 73 chronic myeloid leukemia patients receiving first-line imatinib and compared patients with molecular warning response (WR) with patients with optimal response (OR) and failure regarding short- and long-term outcomes. The cumulative major molecular response (MMR) rates in patients with OR were significantly higher at any timepoint than those achieved by the WR group. Patients with WR at 3 months had significantly inferior failure-free survival (FFS) than optimal responders, but overall survival (OS) was similar. At 6 and 12 months, the WR and OR groups had similar FFS and OS. Twenty of 23 patients with WR at 12 months achieved MMR with imatinib.